AU2012342562B2 - 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors - Google Patents

3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors Download PDF

Info

Publication number
AU2012342562B2
AU2012342562B2 AU2012342562A AU2012342562A AU2012342562B2 AU 2012342562 B2 AU2012342562 B2 AU 2012342562B2 AU 2012342562 A AU2012342562 A AU 2012342562A AU 2012342562 A AU2012342562 A AU 2012342562A AU 2012342562 B2 AU2012342562 B2 AU 2012342562B2
Authority
AU
Australia
Prior art keywords
formula
compound
fluoro
isoquinolin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012342562A
Other languages
English (en)
Other versions
AU2012342562A1 (en
Inventor
Alessandra Cirla
Matteo D'anello
Gianluca Mariano Enrico Papeo
Alessandra Scolaro
Fabio Zuccotto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012342562(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of AU2012342562A1 publication Critical patent/AU2012342562A1/en
Application granted granted Critical
Publication of AU2012342562B2 publication Critical patent/AU2012342562B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012342562A 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors Ceased AU2012342562B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11190687.1 2011-11-25
EP11190687 2011-11-25
EP12161489 2012-03-27
EP12161489.5 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (2)

Publication Number Publication Date
AU2012342562A1 AU2012342562A1 (en) 2014-07-10
AU2012342562B2 true AU2012342562B2 (en) 2017-02-23

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012342562A Ceased AU2012342562B2 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors

Country Status (14)

Country Link
US (1) US9422243B2 (OSRAM)
EP (1) EP2788328B1 (OSRAM)
JP (1) JP6106182B2 (OSRAM)
KR (1) KR20140097457A (OSRAM)
CN (1) CN103946214B (OSRAM)
AU (1) AU2012342562B2 (OSRAM)
BR (1) BR112014012031A2 (OSRAM)
CA (1) CA2856759A1 (OSRAM)
CL (1) CL2014001323A1 (OSRAM)
EA (1) EA027800B1 (OSRAM)
ES (1) ES2676068T3 (OSRAM)
IN (1) IN2014CN04671A (OSRAM)
MX (1) MX2014006015A (OSRAM)
WO (1) WO2013076090A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20180163271A1 (en) * 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
MY194461A (en) 2015-11-06 2022-11-30 Neurocrine Biosciences Inc N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
TW202134231A (zh) 2019-12-06 2021-09-16 美商紐羅克里生物科學有限公司 蕈毒受體4拮抗劑及使用方法
US20250352539A1 (en) 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer
KR20260010420A (ko) 2023-05-11 2026-01-20 아스트라제네카 아베 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010133647A1 (en) * 2009-05-21 2010-11-25 Nerviano Medical Sciences S.R.L. Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60218458T2 (de) * 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010133647A1 (en) * 2009-05-21 2010-11-25 Nerviano Medical Sciences S.R.L. Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors

Also Published As

Publication number Publication date
CL2014001323A1 (es) 2014-09-05
US20140336192A1 (en) 2014-11-13
CA2856759A1 (en) 2013-05-30
BR112014012031A2 (pt) 2017-05-30
HK1200166A1 (en) 2015-07-31
US9422243B2 (en) 2016-08-23
JP6106182B2 (ja) 2017-03-29
IN2014CN04671A (OSRAM) 2015-09-18
EA201491026A1 (ru) 2014-11-28
CN103946214A (zh) 2014-07-23
EA027800B1 (ru) 2017-09-29
EP2788328B1 (en) 2018-01-31
KR20140097457A (ko) 2014-08-06
EP2788328A1 (en) 2014-10-15
WO2013076090A1 (en) 2013-05-30
ES2676068T3 (es) 2018-07-16
JP2014533709A (ja) 2014-12-15
AU2012342562A1 (en) 2014-07-10
MX2014006015A (es) 2014-06-04
CN103946214B (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
CA2762226C (en) Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
EP2454236B1 (en) 3-oxo-2,3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
US9422243B2 (en) 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
EP2454237B1 (en) 3-oxo-2,3,-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
US9073893B2 (en) 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors
HK1200166B (en) 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
HK1166076B (en) Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired